Trial · NCT07898670
Effects of Ashwagandha Supplementation on Quality of Life and Well-Being in Women With Endometriosis
NCT07898670, Not applicable, Not yet recruiting, Medical University of Vienna
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Ashwagandha Supplementation on Quality of Life and Well-Being in Women With Endometriosis. Trials, record NCT07898670. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07898670
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Ashwagandha Supplementation on Quality of Life and Well-Being in Women With Endometriosis
- NCT number
- NCT07898670
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 90 participants, estimated
- Lead sponsor
- Medical University of Vienna
- Conditions
- Endometriosis, Quality of Life, Pain, Perceived Stress, Psychological Well Being
- Interventions
- Ashwagandha, placebo capsule
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in the 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) score | Baseline and end of the initial randomized phase at 12 weeks (up to 16 weeks if extended to align with the menstrual cycle). | Between-group difference in change from baseline to the end of the initial randomized phase in the SF-36 Mental Component Summary (MCS) score, comparing ashwagandha with placebo. The MCS assesses mental health-related quality of life and is calculated using a standardized, norm-based scoring algorithm, with a reference population mean of 50 and a standard deviation of 10. Higher scores indicate better mental health-related quality of life. |
| Secondary | Change in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) score | Baseline to the end of the initial randomized phase at Week 12 (up to Week 16 if extended to align assessments with the menstrual cycle). | Between-group difference in change from baseline to the end of the initial randomized phase in the SF-36 Physical Component Summary (PCS) score, comparing ashwagandha with placebo. The PCS assesses physical health-related quality of life and is calculated using a standardized, norm-based scoring algorithm, with a reference population mean of 50 and a standard deviation of 10. Higher scores indicate better physical health-related quality of life. |
| Secondary | Change in 36-Item Short Form Health Survey (SF-36) domain scores | Baseline to the end of the initial randomized phase at Week 12 (up to Week 16 if extended to align assessments with the menstrual cycle). | Between-group differences in change from baseline to the end of the initial randomized phase in the eight domains of the 36-Item Short Form Health Survey (SF-36), comparing ashwagandha with placebo: physical functioning, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, pain, and general health. Each domain is scored separately on a scale from 0 to 100, with higher scores indicating better health-related quality of life. |
| Secondary | Change in Endometriosis Health Profile-30 global score | Baseline to the end of the initial randomized phase at Week 12 (up to Week 16 if extended to align assessments with the menstrual cycle). | Between-group difference in change from baseline to the end of the initial randomized phase in endometriosis-related quality of life, assessed using the Endometriosis Health Profile-30 (EHP-30) global score, comparing ashwagandha with placebo. Scores range from 0 to 100, with lower scores indicating better endometriosis-related quality of life. |
| Secondary | Change in perceived stress | Baseline to the end of the initial randomized phase at Week 12 (up to Week 16 if extended to align assessments with the menstrual cycle). | Between-group difference in change from baseline to the end of the initial randomized phase in perceived stress, assessed using the 10-item Perceived Stress Scale (PSS-10), comparing ashwagandha with placebo. The total score ranges from 0 to 40, with higher scores indicating greater perceived stress. |
| Secondary | Participant-reported pain-management strategies and pain medication use | Baseline to the end of the initial randomized phase at Week 12 (up to Week 16 if extended to align assessments with the menstrual cycle). | Comparison between the ashwagandha and placebo groups of participant-reported pain-management strategies, including total pain medication (name, number, dosage) use during the menstrual cycle. |
| Secondary | Change in participant-reported dyspareunia | Baseline to the end of the initial randomized phase at Week 12 (up to Week 16 if extended to align assessments with the menstrual cycle). | Between-group difference in change from baseline to the end of the initial randomized phase in participant-reported pain during sexual intercourse (dyspareunia), comparing ashwagandha with placebo. Pain intensity is assessed using an 11-point Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain), with higher scores indicating greater pain intensity. |
| Secondary | Within-person change in the 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) during the open-label extension | Start of the open-label extension to its completion 12 weeks later (approximately study Week 12-24, or Week 16-28 if the initial phase is extended). | Within-person change in the SF-36 Mental Component Summary (MCS) score from the start to the end of the open-label extension, during which participants receive ashwagandha. The MCS assesses mental health-related quality of life and is calculated using a standardized, norm-based scoring algorithm, with a reference population mean of 50 and a standard deviation of 10. Higher scores indicate better mental health-related quality of life. |
| Secondary | Within-person change in the 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS ) during the open-label extension | Start of the open-label extension to its completion 12 weeks later (approximately study Week 12-24, or Week 16-28 if the initial phase is extended). | Within-person change in the SF-36 Physical Component Summary (PCS) score from the start to the end of the open-label extension, during which participants receive ashwagandha. The PCS assesses physical health-related quality of life and is calculated using a standardized, norm-based scoring algorithm, with a reference population mean of 50 and a standard deviation of 10. Higher scores indicate better physical health-related quality of life. |
| Secondary | Within-person change in the Endometriosis Health Profile-30 (EHP-30) during the open-label extension | Start of the open-label extension to its completion 12 weeks later (approximately study Week 12-24, or Week 16-28 if the initial phase is extended). | Within-person change in the Endometriosis Health Profile-30 (EHP-30) global score from the start to the end of the open-label extension, during which participants receive ashwagandha. The EHP-30 assesses endometriosis-related quality of life. Scores range from 0 to 100, with lower scores indicating better endometriosis-related quality of life. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07898670
GET https://conductscience.org/api/trials/v1/NCT07898670/registered